News of 5AM's two latest venture funds follows the launch of Longevity Vision Fund as well as LA BioMed's and RUNLABS’ announcements that they will open new incubators in 2019. Also, Passage Bio launches with $115.5m, but the largest recent VC deal was HaiHe's $146.6m financing.

Sun Zhigang is leaving his cabinet position in China to become the deputy head of southwestern Guizhou province, leaving many wondering about the future direction of the massive effort to provide universal health coverage, improve quality and reduce costs for China’s population. Personnel changes are also taking place at Sanofi and Eisai in Japan, GSK in Southeast Asia and the Chinese association Sino-PhiRDA.

Sun Zhigang is leaving his cabinet position in China to become the deputy head of southwestern Guizhou province, leaving many wondering about the future direction of the massive effort to provide universal health coverage, improve quality and reduce costs for China’s population. Personnel changes are also taking place at Sanofi and Eisai in Japan, GSK in Southeast Asia and the Chinese association Sino-PhiRDA.

In a golden age of biotech in China, Crown is transforming from a biologics development service company to a mixed biotech through a planned IPO in Taiwan. Backed by its world-largest patient-derived xenograft models bank, the company is discovering oncology compounds.